SCHEMBL2448864

SCHEMBL2448864

COc1c(C(C)(C)C)cc(-c2ccc[nH]c2=O)c2ncc(N3CC[C@H](CNS(C)(=O)=O)C3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
IRAK1 P51617 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMO Q99835 1/20 0.34
JAK2 O60674 5/20 0.34
JAK1 P23458 5/20 0.34
TYK2 P29597 5/20 0.34
JAK3 P52333 5/20 0.34
ENPP1 P22413 2/20 0.33
GAK O14976 1/20 0.31
PIK3CD O00329 2/20 0.31
PIK3R1 P27986 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CB P42338 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796409 1.00 CYP3A4 (0.40) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL2448559 0.95 CYP3A4 (0.41) CYP3A4IRAK1SMOJAK2JAK1
SCHEMBL1702705 0.89 CYP3A4 (0.38) CYP3A4
SCHEMBL2452207 0.88 IRAK1 (0.35) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL1703017 0.88 IRAK1 (0.35) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL2448595 0.88 AURKA (0.36) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL1703312 0.86 IRAK1 (0.34) IRAK1KDM4EALDH1A1GAAMAPT
SCHEMBL2452968 0.86 IRAK1 (0.34) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL16508298 0.86 JAK2 (0.34) CYP3A4IRAK1KDM4EALDH1A1GAA
SCHEMBL1702753 0.85 IRAK1 (0.36) IRAK1KDM4EALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP claimed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 US claimed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US claimed
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP disclosed
US-8487103-B2 Quinoline inhibitors of hepatitis C virus polymerase ROCHE PALO ALTO LLC (US) 2013-07-16 US disclosed
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-12-08 US disclosed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 US disclosed
WO-2010142656-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 WO disclosed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US disclosed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 CYP3A4 50/4885IRAK1 2850/4885KDM4E 1276/4885
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, ZC3HAV1, IRF3 CYP3A4 55/4885IRAK1 2103/4885KDM4E 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.